MSD

News

Imfinzi faces Keytruda competition in biliary tract cancer

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with ch

News

GSK claims a first with Jemperli in endometrial cancer

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.

News

ESMO: Trials end 20-year hiatus in cervical cancer therapy

Amid all the new high-tech therapies on display at the ESMO cancer conference, a study funded by Cancer Research UK has shown what can be achieved with cheap generic drugs

News

ESMO: Immunotherapy combos extend lives in bladder cancer

In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer.

News

ESMO: Opdivo chases Keytruda in perioperative lung cancer

Just days after MSD claimed an FDA approval for Keytruda as a pre- and post-surgery option for early non-small cell lung cancer (NSCLC), Bristol-Myers Squibb has staked a

News

MSD sinks $4bn upfront into ADC pact with Daiichi Sankyo

Daiichi Sankyo’s antibody-drug conjugate (ADC) franchise has generated another massive licensing deal, this time from MSD, which is paying $4 billion upfront for rights to

Imfinzi faces Keytruda competition in biliary tract cancer

GSK claims a first with Jemperli in endometrial cancer

ESMO: Trials end 20-year hiatus in cervical cancer therapy

ESMO: Immunotherapy combos extend lives in bladder cancer

ESMO: Opdivo chases Keytruda in perioperative lung cancer

MSD sinks $4bn upfront into ADC pact with Daiichi Sankyo

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

MSD

Editor's Picks